

AstraZeneca Mentoring

Facilitates access to highly skilled mentors within pharmaceutical and companion diagnostic development and commercialisation. Companies are expected to provide key questions that they require guidance on that will be addressed during a 2 hour face to face meeting at AstraZeneca.

Investment: 2,500kr (value 10,000kr)

Duration: 2-3 weeks

Delivered by Aleap AS in collaboration with AstraZeneca

Send email to info@aleap.no for ordering this package



WHY MENTORING?

Innovation is never easy and the numbers tell us that most startups fail due to poor understanding of the market, customers and their ability to deliver their idea to market. In pharmaceutical and diagnostic industries it becomes more challenging as complex regulatory, clinical and reimbursement requirements can be particularly difficult to navigate.

As an entrepreneur the way to market can appear overwhelming and complex.

We don't want these challenges to stand in the way of your great idea. We want to ensure that you have access to leading subject matter experts who can provide guidance on these complexities in a collaborative and cost-effective way.

This service package offers access to experts with extensive experience from the pharmaceutical industry. Their mentoring will allow you to address and potentially resolve critical questions and challenges you have with regards to product development and commercialization.

We want to make sure that you have access to the best industry experts to expedite your market entry.




MENTORING PROGRAM

Define key questions

Identify key questions to be addressed by mentors

Relevant topics:

- Regulatory matters such as documentation requirements, filing procedures and compliance
- Clinical trial considerations such as design, set up and execution
- Formulation questions and drug delivery options



Mentor meeting

In person 2hr discussion with relevant experts within AstraZeneca

Typical agenda:

- Introduction including high level pitch by company
- Presentation of key topics of interest and discussion/experience sharing by experts
- Identification of actions and owners



PRACTICALITIES

Confidentiality

There will be no CDA in place during this mentoring program so discussions should be kept at a generic level regarding processes and experience sharing. Parties are advised from sharing confidential or business sensitive information with the other party.

Meet up in person

In order to get the most out of this program we expect that companies meet in person at either the ALEAP incubator at the Oslo Science Park or at the offices of AstraZeneca in Gothenburg.

Allocate time

Your success in this program is dependent on the effort that you put into it.

Engage resources

As you identify the key topics to be addressed during the program be sure to reach out to your network. Incorporating numerous and ideally differing perspectives to inform areas of focus will be important for program success.

Reach out to the ALEAP team if you have any questions about the process.



RESPONSIBILITIES, DELIVERABLES & INVESTMENT

Aleap will manage the end to end delivery of the mentor program. This includes:

- Overall project management and coordination between the program parties
- Support AstraZeneca in the identification of suitable mentors
- Coordination of mentor meeting

Companies will be expected to:

- Share high level background on company and identify key topics that they are seeking guidance on
- Participate in a face to face meeting

Deliverables from this program includes:

- Expert advice on how to address to key pharmaceutical and diagnostic development and commercialization challenges
- Identification of next steps and actions that can further support company goals
- Connection to expert networks (where and when relevant)

Investment:

AstraZeneca Mentor Program: 2,500 NOK (Value 10,000 NOK – Aleap expenses only)

Want to learn more?



info@aleap.no

<http://www.aleap.no>